Predictive value of serum galectin-3 levels in patients with acute heart failure with preserved ejection fraction

Carrasco-Sánchez, Francisco Javier; Aramburu‐Bodas, Óscar; Salamanca‐Bautista, Prado; Morales-Rull, J.L.; Galisteo-Almeda, Luis; Páez‐Rubio, María Inmaculada; Arias‐Jiménez, José Luis; Aguayo-Canela, Mariano; Pérez-Calvo, Juan Ignacio

doi:10.1016/j.ijcard.2013.08.081

Cited by 76 publications

(41 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…23 Gal-3 was shown to predict all-cause and cardiovascular death, and incident heart failure also in healthy subjects, 19,24,25 in patients with peripheral artery disease, 17 and in those with acute coronary syndrome. In the latter, it also predicted hospitalizations for heart failure, 14 reinfarction, 15 heart failure, and cardiovascular mortality.…”

Section: Prognostic Effect Of Gal-3mentioning

confidence: 93%

Galectin-3 Predicts Long-Term Cardiovascular Death in High-Risk Patients With Coronary Artery Disease

Maiolino

Rossitto

Pedon

et al. 2015

ATVB

101

View full text Add to dashboard Cite

Objective— Galectin-3 (Gal-3) can affect atherogenesis by multiple mechanisms, but it remains scarcely known whether plasma Gal-3 levels predict cardiovascular events in patients with coronary artery disease. Therefore, we investigated if Gal-3 predicts cardiovascular death in patients with coronary artery disease of the Genetic and ENvironmental factors In Coronary Artery disease study. Approach and Results— In a prospective cohort study, we measured the plasma levels of Gal-3 in 1013 randomly selected patients who underwent coronary angiography and long-term follow-up to assess incident cardiovascular events. The primary end points were (1) cardiovascular death and (2) a composite of cardiovascular death, acute coronary syndrome, and stroke. Secondary end points entailed (1) acute myocardial infarction, (2) stroke, and (3) a composite fatal ischemic event including fatal myocardial infarction and stroke. The effect of Gal-3 on prognosis was assessed using Kaplan–Meier analysis and multivariate Cox’s regression. During long-term follow-up (median, 7.2 years), 115 cardiovascular deaths occurred (15.2%), more commonly in the high Gal-3 tertile (25.2%) than in the intermediate and the low tertiles (13.6% versus 7.5%, respectively; P <0.001). The adverse prognostic effect of high Gal-3 was confirmed in subgroup analysis of the patients with angiographically documented coronary artery disease and also of those with a normal left ventricular ejection fraction. At multivariate analysis, Gal-3 was a predictor of cardiovascular mortality (hazard ratio, 1.79; 95% confidence interval, 1.10–2.93; P =0.020) along with age, left ventricular ejection fraction, and coronary atherosclerotic burden. Conclusions— In high cardiovascular risk patients referred for coronary angiography Gal-3 is a strong independent predictor of cardiovascular death.

show abstract

Section: Prognostic Effect Of Gal-3mentioning

confidence: 93%

Galectin-3 Predicts Long-Term Cardiovascular Death in High-Risk Patients With Coronary Artery Disease

Maiolino

Rossitto

Pedon

et al. 2015

ATVB

101

View full text Add to dashboard Cite

show abstract

“…The role of Gal-3 in patients with HF and preserved LV EF seems to be stronger than in patients with reduced LV EF. In a study by Carrasco-Sanchez et al [34], Gal-3 was measured in 419 patients with HF and only slightly decreased EF (inclusion criterion: EF had to be more than 45%). During the follow-up, 219 patients underwent re-hospitalisation or died.…”

Section: Gal-3 and Hf Diagnosis And Prognosismentioning

confidence: 99%

Biomarkers of apoptosis, inflammation, and cardiac extracellular matrix remodelling in the prognosis of heart failure

Osmančík

Louckova

2017

Kardiol Pol

View full text Add to dashboard Cite

“…Observational studies suggest a role for Gal-3 in the development of adverse cardiac remodeling [2,3]. In a clinical setting, it has been proposed to predict heart failure (HF) [4] and all-cause mortality in the general population [4,5] as well as being a marker of an increased risk of CV events in patients with HF [3,6,7], especially those with diastolic dysfunction [7,8,9]. It has also been suggested that Gal-3 may be used to guide medical therapy in patients with HF [10,11].…”

Section: Introductionmentioning

confidence: 99%

Circulating Galectin-3 Levels Are Increased in Patients with Ischemic Heart Disease, but Are Not Influenced by Acute Myocardial Infarction

Singsaas

Manhenke²,

Dickstein³

et al. 2016

Cardiology

View full text Add to dashboard Cite

Objectives: Galectin-3 (Gal-3) is involved in cardiac inflammation and fibrosis, and is in use as a biomarker that indicates increased risk in heart failure. This study examined the relationship between Gal-3 levels and acute and old myocardial infarction (MI) in patients assessed by cardiac magnetic resonance (CMR) imaging. Methods: Group 1 consisted of 38 patients with ST-elevation MI and single-vessel disease treated with primary percutaneous coronary intervention (PCI). Group 2 consisted of 52 patients with prior complicated MI. Twenty-two controls were included. CMR was performed in group 1 at 2 days, 1 week, 2 months and 1 year following PCI and in group 2 at >4 years after MI. Results: Median Gal-3 was elevated in patients compared with controls, group 1: 11.93 ng/ml (IQR 6.34-17.52, p = 0.03), group 2: 12.96 (IQR 6.33-19.29, p = 0.03) and controls: 10.16 (IQR 5.59-14.73). Gal-3 levels did not change during acute MI, and there was no relationship between Gal-3 and infarct size, troponin-T, high-sensitivity C-reactive protein, left-ventricular (LV) volumes or LV ejection fraction (LVEF) in group 1. In group 2, Gal-3 correlated modestly with MI size (r = 0.28, p < 0.05), LV end-diastolic volume index (r = 0.40, p < 0.01), LV end-systolic volume index (r = 0.43, p < 0.01) and LVEF (r = -0.39, p < 0.01). Conclusion: There was no relationship between Gal-3 levels and acute ischemic myocardial injury. A significant, modest relationship between Gal-3 levels, MI size and LV remodeling was only found in patients with old MI.

show abstract

Predictive value of serum galectin-3 levels in patients with acute heart failure with preserved ejection fraction

Cited by 76 publications

References 29 publications

Galectin-3 Predicts Long-Term Cardiovascular Death in High-Risk Patients With Coronary Artery Disease

Galectin-3 Predicts Long-Term Cardiovascular Death in High-Risk Patients With Coronary Artery Disease

Biomarkers of apoptosis, inflammation, and cardiac extracellular matrix remodelling in the prognosis of heart failure

Circulating Galectin-3 Levels Are Increased in Patients with Ischemic Heart Disease, but Are Not Influenced by Acute Myocardial Infarction

Contact Info

Product

Resources

About